Cancer Moonshot Biobank Online Catalog
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $700,000 to $1,500,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 518210 Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health plans to procure operation of the Cancer Moonshot Biobank Online Catalog in full production, with an estimated solicitation release date of March 1, 2026 and an estimated award date of July 1, 2026. Information Management Services, Inc. (IMS) already developed the catalog under a call to a parent NCI Blanket Purchase Agreement, holds an active Authority to Operate, and maintains the system in production-ready mode, with production support to be awarded as a new task order under an existing NCI IDIQ contract on which IMS is a prequalified offeror. This forecast resubmits NIH-NCI-DCTD-007, which received PAA_DER approval on January 14, 2026, because that approval was used on an existing contract due to time constraints.
The estimated award value range is $700,000 to $1,500,000, classified under NAICS 518210 (Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services), with no set-aside used. The Biobank is collecting donated tissue and blood biospecimens from patients nationwide on standard-of-care cancer therapy, and the catalog is intended to launch for biospecimen distribution when the Biobank is ready in 2026. Points of contact are Ping Guan, Program Director (ping.guan@nih.gov, (240) 276-5711), and Jeremy White, Branch Chief/Contracting Officer (jeremy.white@nih.gov, (301) 402-4572).
Forecast text
This is the same request as NIH-NCI-DCTD-007 that received PAA_DER approval on Jan.14. 2026. This is a resubmission since the previous approval has been used on an existing contract due to time constraints.
Biospecimens (for example, tissue and blood) donated by patients are a critical resource for cancer research. The Cancer Moonshot Biobank (Biobank) is a clinical study that is collecting biospecimens from patients across the country who are on standard of care cancer therapy. The biospecimens and associated medical data are being collected over the course of patients' cancer treatment and when complete will be a unique public resource for cancer treatment research. The biospecimens will be provided to researchers through a web-based Online Catalog. The Catalog system has already been developed by Information Management Services, Inc. (IMS) under a Call to a parent NCI Blanket Purchase Agreement (BPA). Significant investment of funds, time, and effort has already been made to establish system requirements, data requirements, data delivery mechanisms, and an active federal Authority to Operate (ATO). The system is currently being minimally maintained in production-ready mode to allow a quick switch to full production when the Biobank is ready for biospecimen distribution in 2026. Operation of the Catalog system in production will be supported by a new TO to an existing NCI Indefinite Delivery/Indefinite Quantity (IDIQ) contract where IMS is one of the prequalified offerors. The new TO requirements are within the scope of the IDIQ. Launching the Catalog system in full production will streamline the biospecimen distribution from the Biobank and maximize the program's overall return on investment.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast